G.ST Antivirals

A heartfelt thank you to FFG Österreichische Forschungsförderungsgesellschaft mbH for featuring us as a “success story.” Their support has been essential in helping us pursue our vision. We appreciate the recognition and look forward to continuing our collaboration as we move ahead 🙏💡 https://lnkd.in/dTxR8VEP

Today we want to acknowledge our dedicated team and everyone supporting G.ST Antivirals! 👏✨   As we continue our Phase 2 trial with our 2-Deoxyglucose nasal spray targeting upper respiratory infections, we’re especially grateful for the hard work of our lab team. Your dedication is essential for the success of this study. Thank you for your ongoing support. 🙌🔬

Yesterday, our CEO Guido Gualdoni, MD, PhD had the pleasure of hosting the BIOTECH AUSTRIA CEO Lunch. It was a great opportunity to present our efforts to develop broad-spectrum antivirals against respiratory tract infections and connect with fellow biotech leaders. The engaging discussion and interesting questions over lunch and coffee added great value to the session. A big thank you to BIOTECH AUSTRIA for organizing this fantastic event, and to Valneva for generously providing the venue. We are looking forward to more opportunities to connect! 🤝 #Biotech #Networking #Antivirals

Excited to announce that Guido Gualdoni, MD, PhD, our CEO, and our Head of Pharmaceutical Development Snezana Radivojev are participating in the MedTechForum in Vienna! This premier event brings together the brightest minds in medical technology to discuss the latest advancements and innovations in the field. We're looking forward to engaging with industry leaders, sharing our insights on antiviral treatments for respiratory tract infections, and exploring new opportunities for collaboration. Join us as we drive forward the future of biotech and medical technology! #MedTechForum #Biotech #Innovation #InfectiousDiseases #Vienna

🔬🌟 Today on Clinical Trials Day, we celebrate the contributions of clinical research professionals and trial participants in advancing healthcare. ⏳ Clinical Trials Day on May 20 commemorates the day in 1747 when the physician James Lind conducted what is considered the first controlled #ClinicalTrial of the modern era, revolutionizing medical research. 🧪 At G.ST Antivirals, we are advancing our Phase II clinical trial with our lead asset, a broad-spectrum antiviral nasal spray containing 2-Deoxy-D-Glucose., to treat respiratory tract infections. Recruitment for our trial is progressing smoothly and we anticipate the data in the second half of this year. 🙌 We are deeply grateful to the trial participants whose involvement is essential to bringing our broad-spectrum antivirals closer to patients in need. A big thank you also to our exceptional trial center Centre for Human Drug Research in Leiden, the Netherlands for their dedication and expertise. And last but certainly not least, thank you to our dedicated team here at G.ST Antivirals! Together, we are striving to make a meaningful impact in the fight against disease and today we celebrate the collective effort that makes it all possible. 🎉 To learn more about our work at G.ST Antivirals, please visit our website www.gst-antivirals.com Ingrid de Visser - Kamerling Victor Cnossen #ClinicalTrialsDay #MedicalResearch #antiviral #Rhinovirus #PhaseII

Our CEO Guido Gualdoni, MD, PhD is meeting partners at the LSX World Congress in London today and tomorrow- reach out if you are around!

🎉 Exciting news from G.ST Antivirals continue! We're thrilled to announce that our Chief Scientific Officer, Anna-Dorothea Gorki, has been nominated as a Voice of a New Era of Leaders by the female factor. This nomination reflects the innovative spirit and leadership that Anna-Dorothea brings to our team and the biotech community. Congratulations, Thea! We are immensely proud of your well-deserved recognition. #Leadership #Innovation #Biotech #FemaleFactor #TeamPride https://lnkd.in/dy5zyYBb

We are excited to share two major announcements today 🎉 🌟 Please join us in welcoming Ronald Bruce Turner, our new Chief Medical Officer, to the team! Ron brings a wealth of experience in the field of respiratory viral infections and is a globally recognized Key Opinion Leader. He is a former Professor of Pediatric Infectious Diseases at the University of Virginia Medical School, has published over 140 articles, reviews and book chapters and advised numerous companies researching respiratory viral infections. Ron will oversee our current clinical trial and drive further clinical development at G.ST Antivirals. We are very much looking forward to working together! 🧪 We have started our Phase II clinical trial with 2-DG: Our lead asset, a broad-spectrum antiviral nasal spray containing 2-Deoxy-D-glucose (2-DG) has entered a Phase 2 study and the first subject was dosed on April 2nd, 2024. The randomized, double-blind, placebo-controlled Phase II rhinovirus-challenge study is conducted at the Centre for Human Drug Research in Leiden, the Netherlands. We are excited to advance our clinical development and bring our promising broad-spectrum antivirals closer to patients in need 🩺 Read the full press release here: https://lnkd.in/d7ghM7Zn

🌟 Big News from Our Team! 🌟 We're very proud as our Chief Scientific Officer, Anna-Dorothea Gorki, is awarded the State Prize by the Federal Minister of Science Dr. Martin Polaschek for her pioneering work in developing in vitro lung models. A huge congratulations to Anna-Dorothea- Here’s to many more achievements! #Biotech #Innovation #TeamPride

Another piece of data showing that despite progress in RSV infections, too many infants will continue to suffer from life-threatening respiratory infections by other viruses. An additional motivation for us at G.ST Antivirals to do everything we can to deliver antiviral options for the most vulnerable among us! https://lnkd.in/dgWyaAaV